Kinnate Biopharma

Kinnate lays off 70% of staff, pulls back from programs to save cash after data disappointment
Fierce Biotech
Tue, 09/19/23 - 10:36 am
Kinnate Biopharma
cancer
layoffs
exarafenib
Kinnate Biopharma upsizes IPO and prices above range at $20 a share
Marketwatch
Fri, 12/4/20 - 10:53 am
Kinnate Biopharma
IPOs
NASDAQ
small molecule kinase inhibitors
Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies
Xconomy
Wed, 08/26/20 - 11:39 pm
Kinnate Biopharma
cancer
oncology